文献速递肺结节与肺癌

美国肺结节评估与管理的当代实践:一项混合方法研究

Contemporary Pulmonary Nodule Evaluation and Management in the United States A Mixed-Methods Study
RSS 订阅 · PubMed 顶刊 · 肺结节与肺癌筛查 · 2026-07-28

该研究于2024年8月至2025年12月通过定性访谈与全国在线调查,探索临床医生肺结节评估管理实践及障碍。3588名受邀医生中192名完成调查,多数使用风险评估工具,71.4%认为评估具挑战性,仅50.5%拥有充足资源。

要点

  • 多数医生使用临床风险预测模型评估肺结节风险,商业生物标志物使用较少。
  • 医生普遍认同肺结节评估需多学科协作与共享决策,但资源不足是主要障碍。
  • 改进优先级应聚焦系统级肺结节追踪与癌症风险评估工具。

核心结论

  • 临床医生认为肺结节评估具有挑战性,需要多学科协作、共享决策和改进,但许多人缺乏提供最佳诊疗所需的资源。
  • 未来应聚焦于改善系统级肺结节追踪和癌症风险评估。

研究设计与样本

  • 探索性序贯混合方法研究,纳入2024年8月至2025年12月期间照护肺结节患者的临床医生。
  • 先对40名多专科临床医生进行半结构化定性访谈,主题分析后开发并实施全国定量在线调查。
  • 3588名美国临床医生受邀,192名(5.4%)完成调查,涵盖普通呼吸科、介入呼吸科、胸外科及其他专科。

主要发现

  • 70.8%的临床医生报告使用风险评估工具评估肺结节癌症风险,临床风险预测模型(70.3%)较商业生物标志物(18.8%)更常用。
  • 63.5%的参与者认为理想风险评估工具应优先避免漏诊肺癌,而非避免不必要的侵入性操作。
  • 71.4%的临床医生认同肺结节评估具有挑战性,95.8%认同需要共享决策,91.1%认同需要多学科协作,85.9%认同需要改进。
  • 仅50.5%报告拥有提供最佳肺结节诊疗所需的临床资源。
  • 参与者将肺结节追踪和风险评估工具列为改善肺结节临床诊疗的首要优先事项。

临床怎么用

  • 临床医生应重视肺结节风险评估工具的规范使用,优先选择临床风险预测模型。
  • 肺结节管理应常规纳入共享决策和多学科协作流程。
  • 系统层面应优先建设肺结节追踪体系和癌症风险评估工具以弥补资源不足。

局限性

  • 调查应答率较低(5.4%),可能影响结果的代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chest . 2026 Jul 28:S0012-3692(26)06306-3. doi: 10.1016/j.chest.2026.06.065. Online ahead of print. ABSTRACT BACKGROUND: Effective evaluation and management of pulmonary nodules (PNs) are essential to diagnosing early-stage lung cancers while avoiding unnecessary invasive procedures. There are key knowledge gaps in how clinicians manage PNs and which opportunities for improvement should be prioritized. RESEARCH QUESTION: Which factors contribute to clinicians' PN evaluation and management practices, and what are perceived barriers to optimal clinical care? STUDY DESIGN AND METHODS: From August 2024 to December 2025, an exploratory sequential mixed-methods study of clinicians who care for patients with PNs was performed. First, we conducted semi-structured qualitative interviews with 40 clinicians across multiple specialties prior to thematically analyzing interview transcripts to develop and administer a quantitative online survey nationwide. We descriptively analyzed survey data, triangulated results with representative interview quotes, and performed exploratory analyses assessing factors associated with survey responses selected by a priori study objectives and qualitative findings. RESULTS: Of 3,588 US clinicians invited via email to participate in the survey, 192 (5.4%) across general pulmonology, interventional pulmonology, thoracic surgery, and other specialties completed it. Most clinicians (70.8%) reported using risk assessment tools to evaluate PN cancer risk, with clinical risk prediction models (70.3%) more commonly used than commercial biomarkers (18.8%). Most participants (63.5%) believed that an ideal risk assessment tool should prioritize not missing a lung cancer diagnosis rather than avoiding unnecessary invasive procedures. Clinicians generally agreed that PN evaluation is challenging (71.4%) and requires shared decision-making (95.8%), multidisciplinary collaboration (91.1%), and improvement (85.9%). Only 50.5% reported having the clinical resources necessary to provide optimal PN care. Participants ranked PN tracking and risk assessment tools as the top priorities for improving PN clinical care. INTERPRETATION: Our results show that clinicians find PN evaluation challenging, requiring multidisciplinary collaboration, shared decision-making, and improvement, but many lack adequate resources to provide optimal care. Future efforts should focus on improving system-level PN tracking and cancer risk assessment. PMID: 42521153 | PMC: PMC1348

来源:PubMed 顶刊 · 肺结节与肺癌筛查,查看原文。版权归原作者所有。

引用

  1. PubMed 顶刊 · 肺结节与肺癌筛查:Contemporary Pulmonary Nodule Evaluation and Management in the United States A Mixed-Methods Study

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。